Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
CEO
Deborah L. Birx
IPO Date
May 20, 1994
Website
https://www.armatapharma.com
Phone
858 829 0829
Address
4503 Glencoe Avenue Marina del Rey, CA 90292
Happy Sunday!
Jul 19, 2026
Economic Echoes
On this day in 1870, the Franco-Prussian War began.
